samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > how pharma can conquer the next pandemic
PUBLICATIONS
European Biopharmaceutical Review

How Pharma Can Conquer the Next Pandemic

The COVID-19 pandemic has brought a level of global disruption unseen in most of our lifetimes, with countries around the world continuing to grapple with infection rates and lockdown restrictions.

While we’re still some way away from a realistic end to the crisis, we are starting to see some positive developments rising from the gloom: countries in Europe and Asia are seeing their mitigation and suppression efforts starting to bear fruit, and track and trace systems have been implemented and are improving in efficacy by the day. Treatments, and our general understanding of the virus, are also progressing, with dexamethasone emerging as a viable treatment for the sickest patients. Meanwhile, early clinical trials of several different vaccines have had promising results.

Unsurprisingly, the pharmaceutical industry has led the charge in the battle against COVID-19 in many respects, and will continue to be at the forefront of the global response in the months to come. Given the upheaval that the current outbreak has caused, the way the world responds will act as a blueprint for future pandemics. With this in mind, the pharma industry must learn as many valuable lessons from the situation as possible.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Vladimir Tkachenko, a pharmaceutical sciences expert, is General Manager of Amaxa Pharma, a UK-headquartered pharma company focused on life-threatening therapeutic areas such as oncology and neonatology in the Commonwealth of Independent States countries. Within this role, Vladimir is responsible for the general management and success of the company, developing sales strategy, implementing managerial accounting strategy, preparing operation budgets and licensing. Since joining Amaxa Pharma in 2012, Vladimir has been instrumental in its success in Europe, driving effective partnerships and bringing life-changing prescription and non-prescription medicines for the treatment of patients suffering from cancer, blood-related diseases, premature birth, and other life-threatening illnesses.
spacer
Vladimir Tkachenko
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Top ten tasks to prepare for the UK Conformity Assessment

As the medical device industry gears up to implement a new set of requirements following Brexit, Maetrics has released a concise guide summarizing the known requirements so far and priority areas where manufacturers can give their immediate attention.
More info >>

White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement